The impact of second allogeneic hematopoietic stem cell transplantation as salvage therapy for hematologic diseases after a first allogeneic transplantation

Basit Öğe Kaydı
dc.contributor.authorBatgi, Hikmetullah
dc.contributor.authorZorlu, Tugba
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorUzay, Ant
dc.contributor.authorHindilerden, Ipek Yonal
dc.contributor.authorPepeler, Mehmet Sezgin
dc.contributor.authorApaydin, Merve
dc.date.accessioned2026-04-04T13:34:46Z
dc.date.available2026-04-04T13:34:46Z
dc.date.issued2025
dc.departmentİnönü Üniversitesi
dc.description.abstractBackground and objectives: Acute leukemia patients who relapse after the first allogeneic stem-cell transplantation (HSCT1) have a poor prognosis. Second allogeneic hematopoietic stem-cell transplantation (HSCT2) is a therapeutic option for patients with acute myeloid leukemia (AML)/acute lymphoblastic leukemia (ALL) relapsing after HSCT1. Our aim is to evaluate the efficacy of HSCT2 in acute leukemia patients who relapsed after HSCT1. Material and methods: In the current study, we retrospectively analyzed the data of 72 patients who underwent HSCT2. Forty-six patients with AML and 26 patients with ALL were included in the study. Results: Before undergoing HSCT2, 47 % of patients were in complete remission. Median follow-up was 8 (1-109) months. Mortality at last follow-up was 61.1 %, and the median overall survival was 11 months (95 % CI: 1-22.9). Univariate analysis identified that age, Eastern Cooperative Oncology Group (ECOG), Body Mass Index, chimerism, conditioning regimen, CD34+ infused cell count, post-transplant cyclophosphamide usage, disease type, pre transplant hemoglobin-lymphocyte-lactate dehydrogenase-ferritin might be significant factors. After multivariate analysis ECOG (HR: 2.142; 95 % CI: 1.061-4.326; p = 0.034) was the only independent predictor for survival. Conclusion: HSCT2 remains a feasible but high-risk treatment option for patients with relapsed acute leukemia after HSCT1. Our findings confirm that ECOG performance status is a key determinant of survival despite advances in transplantation techniques.
dc.identifier.doi10.1016/j.transci.2025.104187
dc.identifier.issn1473-0502
dc.identifier.issn1878-1683
dc.identifier.issue4
dc.identifier.orcid0009-0000-2854-0146
dc.identifier.orcid0000-0002-3285-417X
dc.identifier.orcid0000-0001-8605-8497
dc.identifier.pmid40543289
dc.identifier.scopus2-s2.0-105008436759
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1016/j.transci.2025.104187
dc.identifier.urihttps://hdl.handle.net/11616/109398
dc.identifier.volume64
dc.identifier.wosWOS:001519114000003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherPergamon-Elsevier Science Ltd
dc.relation.ispartofTransfusion and Apheresis Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.subjectAcute myeloid leukemia
dc.subjectAcute lymphoblastic leukemia
dc.subjectSecond hematopoietic stem cell transplantation
dc.subjectOverall survival
dc.titleThe impact of second allogeneic hematopoietic stem cell transplantation as salvage therapy for hematologic diseases after a first allogeneic transplantation
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu